Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
At PRA Health Sciences, we work side-by-side with our clients, to move drug discov...
At PRA Health Sciences, we work side-by-side wi...
Gali Health, Inc. is a San Francisco-based consumer-focused health technology comp...
Gali Health, Inc. is a San Francisco-based cons...
CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and a...
CASI is a U.S. NASDAQ-listed biopharmaceutical ...
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse p...
Oncternal Therapeutics is a clinical-stage onco...
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to address...
Foamix Pharmaceuticals is a specialty pharmaceu...
Kitov Pharma is an innovative biopharmaceutical drug development company. Leveragi...
Kitov Pharma is an innovative biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.